The QualityStocks Daily Wednesday, October 3rd, 2018

Today's Top 3 StockMarketWatch

StockMarketWatch (PTIE) +200.55%

StocksToBuyNow (HOILF) +148.96%

MarketClub Analysis (VTVT) +70.00%

The QualityStocks Daily Stock List

Concierge Technologies, Inc. (CNCG)

ProTrader, EpicVIP Group, MomentumOTC, OnPointStockAlert, Penny Stock Prodigy, Penny Stock Titans, The Street, Epic Stock Picks, Nebula Stocks, MicrocapVoice, OTCPicks, PennyStocks24, Pumps and Dumps, TopPennyStockMovers, and Light Speed Stocks reported earlier on Concierge Technologies, Inc. (CNCG), and we also report on the Company, here at the QualityStocks Daily Newsletter.

Concierge Technologies, Inc. is a worldwide conglomerate with operating businesses in financial services, food manufacturing, as well as security systems. The Company has facilities located in the United States, New Zealand, and Canada. OTCQB-listed, Concierge Technologies is based in Valley Center, California.

The Company operates by way of its wholly-owned subsidiaries Original Sprout, Wainwright Holdings, Gourmet Foods, Ltd., and Brigadier Security Systems. Moreover, USCF is a subsidiary of Concierge Technologies. USCF operates at the vanguard of product innovation as an asset management firm offering exchange-traded products (ETPs), exchange-traded funds (ETFs), and mutual funds.

Gourmet Foods is a well-established producer of popular New Zealand meat pies and bakery products under recognized supermarket brand names “Pat’s Pantry” and “Ponsonby Pies”. Gourmet Foods products are in convenience stores, major supermarkets, petroleum stations, and restaurants. Gourmet Foods distributes more than 30 products throughout New Zealand.

In June 2016, Concierge Technologies acquired Brigadier Security Systems of Saskatoon, Saskatchewan. Brigadier is an alarm installation and monitoring company. It is a long-standing security alarm business serving the Province of Saskatchewan since 1985.

Brigadier has security solutions ranging from products designed to protect residential premises and property through to complex access control and camera monitoring equipment. Brigadier Security Systems operates under the trade name Elite Security.

In December 2017, Concierge Technologies acquired all of the assets and business of Original Sprout LLC, a California Limited Liability Company (OS). As of December 19, 2017, it began operations under the fictitious business name "Original Sprout" from its location in San Clemente, California.  Original Sprout is a manufacturer and distributor of clean, non-toxic, all-natural hair care and skin products. It was founded by master hair stylist Inga Tritt in 2003.

This past July, Concierge Technologies announced it will expand the marketing and distribution of its Original Sprout brand of hair and skin care products to New Zealand. The Company said that it will take advantage of the existing resources of its New Zealand-based Gourmet Foods subsidiary to introduce Original Sprout products to the New Zealand market.

Original Sprout produces and distributes a complete line of natural, 100 percent vegan, safe, non-toxic hair and skin care products (including a "reef safe" sun screen) in the U.K., the E.U., Turkey, the Middle East, Taiwan, Singapore, Hong Kong, Malaysia, Canada, the U.S. and its territories.

Concierge Technologies, Inc. (CNCG), closed Wednesday's trading session at $1.05, up 5.00%, on 1,200 volume with 1 trade. The average volume for the last 3 months is 484 and the stock's 52-week low/high is $0.55/$2.997.

chart

Sierra Monitor Corp. (SRMC)

Wall Street Resources, Stock News Now, Zacks, MicroCap Gems, Marketbeat, and SmallCapVoice reported on Sierra Monitor Corp. (SRMC), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Sierra Monitor Corp. is a provider of Industrial Internet of Things (IIoT) solutions, which target facility automation and facility safety requirements. The Company’s FieldServer brand of protocol gateways is used by system integrators and original equipment manufacturers (OEMs) to enable local and remote monitoring and control of assets and facilities. OTCQB-listed, Sierra Monitor is based in Milpitas, California.

FieldServer is the industry’s leading-protocol gateway, with greater than 200,000 products, supporting more than 140 protocols, installed in industrial and commercial facilities.

Sierra Monitor’s industry-leading BACnet gateways, routers, and network explorers are now "IIoT-Empowered out-of-the-box". They are shipping with new software that allows customers to securely register, access, and manage their field-installed products from the Company’s FieldPoP™ device cloud.

The Company offers its BACnet Explorer NG, the industry’s first cloud-connected network discovery and management solution for BACnet networks. BACnet is an industry-standard protocol extensively used in building and facility automation.

The combination of the “plug-and-play” BACnet Explorer NG appliance and Sierra Monitor’s FieldPoP™ device cloud allows installers and system integrators to seamlessly and remotely discover and manage BACnet MS/TP and BACnet/IP devices on an automation network, test newly installed devices, debug the network, upload device and network information to the cloud, integrate device and network data with sophisticated cloud-based software applications, and provide a control path back to the network and devices.

Sierra Monitor’s Sentry IT fire and gas detection solutions are used by industrial and commercial facilities managers to protect their personnel and assets. The latest Sentry IT controller easily consolidates up to 32 separate toxic and/or combustible gas sensors into a single interface panel. Furthermore, the system comes with GlobalCal™, which is Sierra Monitor’s integrated calibration system that necessities less frequent calibration, translating directly into lower total operating expenditures.

In June, Sierra Monitor announced its latest release of FieldServer software that now supports an expanded range of Life Safety objects. The new software is certified by the BACnet Testing Labs (BTL). It supports a new edge-compute functionality designed to simplify integration and improve operation of the OEO function. The Fire Safety Products group at Siemens Building Technologies is an existing FieldServer customer. This group worked with Sierra Monitor to create this enhanced functionality.

Also, in June, Sierra Monitor announced it was named one of the Top Places to Work by the Bay Area News Group (BANG), publisher of the San Jose Mercury News. Within the small business category, Sierra Monitor ranked in the top 10.

Sierra Monitor Corp. (SRMC), closed Wednesday's trading session at $2.00, up 5.26%, on 3,400 volume with 2 trades. The average volume for the last 3 months is 5,585 and the stock's 52-week low/high is $1.149/$2.17.

chart

AmpliTech Group, Inc. (AMPG)

Information Solutions Group, Pumps and Dumps, HoleinOneStocks, HotStockProfits, Trading Wall St, Penny Stock Gainers, RockingPennyStocks, BestStocksDaily, Wallstreetbuzz, fusionspicks, Jet-Life Penny Stocks, OTCMagic, Ascending Stocks, AllPennyStocks, SmallCapVoice, PennyStocks24, and Fortune Penny Stocks reported on AmpliTech Group, Inc. (AMPG), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

AmpliTech Group, Inc. designs, develops, and manufactures custom and standard state-of-the-art RF Low Noise Amplifiers (LNA) and Power Amplifiers (PA). These are for the domestic and international, SATCOM, Space, and Military markets. Additionally, the Company provides consulting services to help with any microwave components or systems design problems. AmpliTech Group has its head office in Bohemia, New York. The Company lists on the OTCQB.

AmpliTech Group’s designs encompass the frequency spectrum from 50 kHz to 40 GHz - eventually providing designs up to 100 GHz. The Company can provide complex, custom solutions for almost any custom requirements presented to it. It can provide contract assembly of customers' own designs.

AmpliTech uses the most contemporary CAD microwave simulation technology to design and develop from concept to final manufacture of a deliverable product with premier accuracy. The Company expects to release new products targeted at the wireless and satellite markets, which will provide advanced technology and performance.

AmpliTech Group provides its customers with consulting services for their system development. Moreover, the Company provides technical assistance in integration and packaging technologies and microwave sub-systems and amplifier related sub-assemblies.

In 2017, AmpliTech Group announced that it entered into a Joint Venture (JV) Agreement with Trusted Networks, Inc. (TN). The focus of the JV is to develop an affordable mixed signal chipset, which can be used at server/router level and in mobile PDA applications to provide secure and encrypted communication with the aim of preventing hacking and cyber-attacks. TN is a New York, New York based private company with facilities in Colorado Springs and Nashua, New Hampshire.

In September, AmpliTech Group announced that it reached 2 million dollars in sales backlog as of mid-September, which is a record milestone. Since profit margins are up by an average of almost 20 percent over last year based on basic job-costing analysis, the expectation is that annual financial reports will show increases in revenue.

Louisa Sanfratello, Chief Financial Officer, said, “The $500,000 in bookings since our last press release on August 3rd is better than anticipated. Combined with positive sales projections for the final quarter, this bodes very well for the overall fiscal year.”

AmpliTech Group, Inc. (AMPG), closed Wednesday's trading session at $0.053, even for the day, on 8,500 volume with 6 trades. The average volume for the last 3 months is 68,503 and the stock's 52-week low/high is $0.0296/$0.396.

chart

Biotricity, Inc. (BTCY)

4-Traders, Finance Registrar, SmallCap Network, Stock News Now, InvestorsHub, Stockhouse, GuruFocus, Barchart, and SECFilings.com News reported earlier on Biotricity, Inc. (BTCY), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Biotricity, Inc. is a medical diagnostic and consumer healthcare technology company headquartered in Redwood City, California. Its dedication is to deliver biometric remote monitoring solutions. The Company delivers these solutions to the medical and consumer markets. This includes diagnostic and post-diagnostic solutions for chronic conditions and lifestyle improvement. Biotricity lists on the OTC Markets Group’s OTCQB.

Biotricity’s vision is putting health management into the hands of the individual. The Company is working to support the self-management of critical and chronic conditions with the use of unique solutions to ease the rising burden on the healthcare system. Biotricity’s Research and Development (R&D) continues to focus on the preventative healthcare market.

The Company has created two ECG monitoring devices. The design of these is to improve upon the tools and devices available in the contemporary market. For Consumers, Biotricity has its Biolife. This is a preventative care solution. It takes advantage of the expertise gained from the Company’s Bioflux.

The design of Biolife is to assist individuals in tracking their progress in real-time so they can stay motivated to make lifestyle changes. Biolife helps users make lifestyle changes through uniting medically relevant ECG data with social media interactivity and a lifestyle log.

For Physicians, Biotricity has its Bioflux. This is a medical technology solution for physicians to test and diagnose patients, and benefit from an innovative system that provides continuing active monitoring for up to 30 consecutive days. Bioflux comprises an ECG monitoring device, software, and also access to a monitoring lab. The Bioflux software component is an acquisition that is already Food and Drug Administration (FDA) cleared. It is a standard for ECG monitoring in hospitals and cardiac clinics.

Yesterday, Biotricity provided operational updates for its fiscal 2018 Q2 that ended September 30, 2018. Bioflux 1.0 sales growth and market expansion attained a record high during the fiscal 2018 Q2; the Company experienced a 150 percent increase in total device sales. It also experienced a 75 percent increase in new customers from Q1.

Biotricity is continuing to develop “Biopatch,” an ECG patch that it anticipates filing with the FDA by Q1 2019. Biopatch is an extension of the Company’s award-winning Bioflux device.

Biopatch offers an alternative to the 3-lead system that is ideal for patients with less complicated cardiac conditions. The patch takes advantage of the capabilities of Bioflux. It provides wireless arrhythmia monitoring for patients who are either at risk for, or diagnosed with, certain cardiac issues.

Biotricity, Inc. (BTCY), closed Wednesday's trading session at $2.28, up 14.00%, on 140,549 volume with 243 trades. The average volume for the last 3 months is 120,004 and the stock's 52-week low/high is $1.179/$19.50.

chart

Investview, Inc. (INVU)

Barchart, Stockflare, Investopedia, Stockhouse, MarketWatch, InvestorsHub, Marketwired, OTC Markets, TradingView, and StockDeputy reported on Investview, Inc. (INVU), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Investview, Inc. is a diversified financial technology company. It operates chiefly through its wholly- and majority-owned subsidiaries. Investview provides financial products and services to accredited investors, self-directed investors, and select financial institutions. The Company has its Wealth Generators wholly-owned subsidiary recently undergoing a name change. Incorporated in 2005, Investview is based in Salt Lake City, Utah.

Wealth Generators’ products are provided to individuals on a monthly subscription basis. Wealth Generators is classified as a publisher of financial research and information and it is exempt from securities registration.

Wealth Generators provides financial technology, education, and research to individuals. Wealth Generators is not a brokerage firm or Registered Investment Advisor. It does not execute trades or take possession of clients' brokerage accounts. Its products undergo distribution through a direct sales model.

On March 1, 2018, Investview announced that it filed a name change for its wholly-owned subsidiary Wealth Generators LLC to Kuvera LLC. Investview changed the name of Wealth Generators to Kuvera LLC in its initial steps to create its vision for its recently acquired LLC.

Investview has released the Kuvera brand in the final transition steps to rename its wholly-owned subsidiary Wealth Generators LLC to Kuvera LLC. Investview completed the transition April 12, 2018 when it unveiled the Kuvera brand by way of a series of live launch webinars, the release of kuveraglobal.com and a comprehensive set of marketing tools to share the Kuvera vision and mission.

In essence, Investview provides education and technology designed to help individuals in navigating the financial markets. The Company’s services include tools and research, newsletter alerts, and live education rooms that comprise instruction on the subjects of equities, options, FOREX, ETF’s, and binary options. In addition, Investview offers education and technology applications to help individuals in debt reduction, enhanced savings, budgeting, and proper tax expense management. Investview has added Crypto mining services and education to its program services.

Earlier in July, Investview released its full year Fiscal 2018 audited financials. Selected financial highlights for the period April 1,2017 to March 31,2018 over Fiscal 2017 include Gross Billings increasing 62 percent or $9.1M from $14.6M to $23.6M. Net Revenue rose 39 percent or $5M from $12.9M to $17.9M.

Investview realized its first quarter of positive cash flow from operations of $1.3M in Q4 of fiscal 2018. The Company had a considerable increase in Net Loss from $2.4M to $14.9M. However, only $1M was cash related.

Investview, Inc. (INVU), closed Wednesday's trading session at $0.019, up 26.67%, on 189,636 volume with 15 trades. The average volume for the last 3 months is 254,769 and the stock's 52-week low/high is $0.0072/$0.10.

chart

Midwest Energy Emissions Corp. (MEEC)

MissionIR, SeriousTraders, Greenbackers, Marketbeat, Wall Street Resources, TopPennyStockMovers, NBT Equities Research, and PennyStocks24 reported on Midwest Energy Emissions Corp. (MEEC), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Midwest Energy Emissions Corp. is a developing leader in mercury emissions control technology for the global coal-power industry. The Company develops and employs patented and proprietary technologies to remove mercury from coal-power plant emissions. Midwest Energy Emissions focuses on the delivery of mercury capture technologies to power plants and other industrial coal-burning units in North America, Europe, and Asia. The Company is based in Lewis Center, Ohio.

Midwest Energy Emissions utilizes patented technology that has been shown to attain mercury removal levels compliant with the U.S. Environmental Protection Agency's (EPA) Mercury and Air Toxic Standards (MATS) rule, at a considerably lower cost and with less operational impact than methods now used. This is while preserving the ability for customers to recycle and sell fly-ash for beneficial use.

The Company’s proprietary SEA™ (Sorbent Enhancement Additive) technology delivers a flexible, tunable solution. It permits the international coal-power industry to easily comply with new, highly restrictive regulations on mercury air emissions.

Midwest Energy Emissions has acquired all patent rights for its Sorbent Enhancement Additive (SEA™) mercury emissions control technology from the Energy & Environmental Research Center Foundation (EERCF of Grand Forks, North Dakota). The SEA™ approach to mercury capture is exactly tailored for each application to complement a customer’s fuel type and boiler configuration for best results. EERCF is an organization that works to provide innovative solutions to the world’s energy and environmental challenges.

Midwest Energy Emissions is adding a new product to its proven, cost-effective mercury capture program. This product will reduce mercury emissions by preventing scrubber reemission events. The design of the product is specifically for coal-fired power utilities with wet scrubbers to help remove mercury and other metals from the scrubber.

This past April, Midwest Energy Emissions announced it secured another order from the Company’s earlier announced Canadian customer to install its proprietary Sorbent Enhancement Additive (SEA™) Technology at another one of their large power plants in the Province of Alberta. Since 2011, Midwest Energy Emissions has worked with this Canadian customer across numerous projects in the United States and Canada.

Midwest Energy Emissions Corp. (MEEC), closed Wednesday's trading session at $0.23, up 4.55%, on 17,730 volume with 6 trades. The average volume for the last 3 months is 47,510 and the stock's 52-week low/high is $0.11625/$0.469.

chart

Regulus Therapeutics, Inc. (RGLS)

Simply Wall St, Zacks, YCharts, InvestorsHub, 4-Traders, MarketWatch, Stockhouse, Nasdaq.com, The Street, Stock Twits, Investor Network, Super Stock Screener, and Stock News Gazette reported on Regulus Therapeutics, Inc. (RGLS), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Regulus Therapeutics, Inc. is leading the discovery and development of innovative medicines targeting microRNAs. The Company is advancing several programs in renal, hepatic and central nervous systems diseases. A clinical stage biopharmaceutical company, Regulus Therapeutics is headquartered in La Jolla, California. The Company was established in September of 2007 by Alnylam Pharmaceuticals (ALNY) and Isis Pharmaceuticals, now Ionis Pharmaceuticals (IONS).

Regulus Therapeutics has taken advantage of its oligonucleotide drug discovery and development expertise to develop a well-balanced microRNA therapeutics pipeline. This pipeline is complemented by a rich intellectual property (IP) estate. All together, this enables the Company to retain its leadership in the microRNA field.

Regulus Therapeutics has its RG-012 for Alport syndrome and RGLS4326 for autosomal dominant polycystic kidney disease (ADPKD). Alport syndrome is an inherited form of kidney disease. It is caused by mutations in the type IV collagen genes (Col4A3, Col4A4 and Col4A5). RG-012 is undergoing development by the Company in a strategic alliance with Genzyme, a Sanofi company, for the treatment of Alport syndrome.

RG-012 is a single stranded, chemically modified oligonucleotide. It binds to and inhibits the function of miR-21 for the treatment of Alport syndrome.

ADPKD is caused by the mutations in the PKD1 or PKD2 genes. ADPKD is among the most common human monogenetic disorders. Additionally, it is a leading genetic cause of end-stage renal disease.

RGLS4326 is a novel oligonucleotide. The design of it is to inhibit miR-17 using a unique chemistry design to preferentially target the kidney.

Regulus Therapeutics and STA Pharmaceutical Co., Ltd. (STA) announced in February 2018 that they entered into an oligonucleotide synthesis collaboration agreement for research and mid-scale non-GMP/cGMP manufacturing. STA is a WuXi AppTec group company and the leading open-access capability and technology platform for small molecule pharmaceutical development and manufacturing.

Concerning RGLS4326 for autosomal dominant polycystic kidney disease (ADPKD), a Phase I SAD study was started in December 2017.  Data from the study in healthy volunteers will provide pharmacokinetics and safety data. Currently, the study is on course for completion in Q3 2018.

Concerning RG-012 for Alport syndrome, patient recruitment activities for the Phase II HERA and the renal biopsy studies are continuing.  Based on revised enrollment assumptions, Regulus believes that both studies will be fully enrolled in the second half of 2018.

In May, Regulus Therapeutics announced that it started a Phase I multiple ascending dose (MAD) study in healthy volunteers for RGLS4326 for the treatment of autosomal dominant polycystic kidney disease, or ADPKD.

Mr. Timothy Wright, M.D., Chief R&D Officer of Regulus Therapeutics, said, "We are pleased to advance the RGLS4326 program with the initiation of the MAD study, which will allow us to further characterize the safety and pharmacokinetic profile of RGLS4326 and establish the dose range that we will study in patients with ADPKD."

This month, Regulus Therapeutics announced a strategic update and corporate restructuring. With the aim of extending its cash runway, the Company has taken certain steps. Recruitment activities for the RG-012 clinical program in Alport syndrome have been paused while discussions with Sanofi to potentially restructure the partnership are continuing.

Preclinical research efforts will center on its Hepatitis B virus (HBV) programs. Moreover, a workforce reduction of roughly 60 percent is being implemented. The Company states that these actions are expected to yield greater than $20 million of annualized savings intended to extend Regulus’ cash runway into mid-2019.

Regulus Therapeutics, Inc. (RGLS), closed Wednesday's trading session at $0.21, up 11.76%, on 1,526,372 volume with 2,053 trades. The average volume for the last 3 months is 1,412,832 and the stock's 52-week low/high is $0.17/$1.50.

chart

Avalon Globocare Corp. (AVCO)

NetworkNewsWire, OTC Markets, Information Vine, Dynamic Wealth Research, Business Insider, Wallet Investor, Whale Wisdom, InvestorsHub, and TradingView reported on Avalon Globocare Corp. (AVCO), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed, Avalon Globocare Corp. provides healthcare services in the U.S. and China. The Company operates via its main platforms: Avalon Cell and Avalon Rehabilitation. Avalon Globocare is a premier healthcare management provider and biotechnology developer. Its commitment is to integrate and manage worldwide healthcare resources. Avalon Globocare has its headquarters in Freehold, New Jersey.

In addition, the Company, through its subsidiary “Avalon RT9 Properties, LLC”, engages in the acquirement and management of healthcare facilities. Regarding Avalon Globocare’s healthcare facility, it currently includes healthcare property management services, chiefly through acquiring and managing healthcare real estate facilities, stem cell banks, and a CAP-certified laboratory, which will complement the Company’s existing platforms.

The “Avalon Rehabilitation” platform is a turnkey, complete set of rehabilitation services. These services include PT, OT, robotic engineering, cybernectics, and clinical nutrition. The Company’s “Avalon Cell” platform focuses on cell-based therapies and technologies. Its concentration is in the field of in vitro diagnostics, regenerative medicine, and cancer immunotherapy.

Avalon Cell focuses on transformative and high-impact cell-based bio-technology opportunities in the U.S. and China. It then fast tracks these to clinical development and commercialization globally.

Avalon Globocare’s majority-owned subsidiary, GenExosome Technologies, Inc., has acquired 100 percent of the outstanding capital stock of Beijing Jieteng (Beijing GenExosome) Biotech Co. Ltd.  GenExosome also entered into and closed an Asset Purchase Agreement with Dr. Yu Zhou, Chief Executive Officer of GenExosome Beijing, where GenExosome acquired all assets, including all intellectual property (IP), patents and patent applications held by Dr. Zhou regarding the business of researching, developing, and commercializing exosome technologies.

Recently, Avalon Globocare announced that it created a joint venture (JV) with Jiangsu Unicorn Biological Technology Co. Ltd. that brings wide-ranging medical resources in Jiangsu Province, China. The partnership was created to lead to the development of a first-class network of provincial centers of excellence for translational research, collaborating in the areas of technological, clinical and regulatory resources in the areas of cellular therapy and bio-banking from leading hospitals.

Last week, Avalon Globocare announced that it established a new wholly-owned U.S. subsidiary, Avactis Biosciences, Inc. This subsidiary will center on fast-tracking commercial activities related to its proprietary Chimeric Antigen Receptor (CAR)-T technologies.

The design of Avactis Biosciences is to integrate and optimize Avalon’s worldwide scientific and clinical resources.  CAR-T is a novel and ground-breaking cancer immunotherapy. It involves genetically modifying T cells to activate the immune system to recognize and destroy cancer cells.

Avalon Globocare Corp. (AVCO), closed Wednesday's trading session at $2.80, up 3.70%, on 7,315 volume with 8 trades. The average volume for the last 3 months is 1,538 and the stock's 52-week low/high is $0.984/$4.59.

chart

Durango Resources, Inc. (ATOXF)

Penny Stock Hub, Stockhouse, OTC Markets, MarketWatch, Barchart, WalletInvestor, High Rising Stocks, OTC Stock Watch, Resource World, InvestorX, Investors Guru, Stockwatch, and Jet Life Penny Stocks reported on Durango Resources, Inc. (ATOXF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Durango Resources, Inc. acquires and explores for precious and base mineral properties in Canada. The Company previously went by the name Atocha Resources, Inc. It changed its name to Durango Resources, Inc. in February 2013. Incorporated in 2006, Durango Resources is based in Vancouver, British Columbia. The Company’s common shares started trading on the OTCQB® Venture Market in the U.S. under the symbol “ATOXF” on March 13, 2018.

Durango Resources has a large asset pool of claims. It has projects in strategic areas adjoining Osisko, Nemaska Lithium, Lakeshore Gold, GT Gold, and Garibaldi Resources.

The Company has 100 percent owned Canadian properties. Its properties include Dianna Lake, Saskatchewan; Whitney Northwest, Ontario; NMX East, Quebec; Decouverte (Discovery), Quebec; Mayner’s Fortune, British Columbia; Windfall Lake Properties, Quebec; and Buckshot Graphite, Quebec.

Durango’s Decouverte Property in James Bay, Quebec had an independent technical review completed as reported on January 16, 2018. The review supports a drilling program of 3,800 meters across 36 holes.

Decouverte is a grassroots gold project. It is targeting greenstone-hosted orogenic gold mineralization. The Decouverte property is 57 square kilometers (5,700 ha). Six target areas are defined on the property. Each of these ranges from 100 meters to 400 meters along strike.

Recently, Durango Resources reported that it will continue to hold 100 percent interest in its Trove Property in Québec. The Trove Property is 1,188 hectares in size. It is amongst the Windfall Lake gold deposit - one of the highest-grade resource stage gold projects in Canada. The Trove claims are in the Windfall-Urban Gold Camp district of northern Québec surrounded by properties held by Osisko Mining, Inc. and are a direct extension of the southwest mineralized trend, which BonTerra Resources, Inc. is exploring on its Gladiator Gold Deposit and Coliseum Gold property.

Last week, Durango Resources announced that it entered into a property purchase agreement to acquire an additional 2,358 hectares in Windfall Lake, Québec. The Property is in a key position of the Urban-Barry Greenstone belt of Québec. It is situated roughly 5.5km south of Osisko Mining’s Black Dog Project, and about 10km south of the Barry Gold Deposit, now owned by BonTerra Resources.

As consideration for a 100 percent interest in the Property, Durango Resources will issue 500,000 common shares, subject to TSX Venture Exchange approval of the property purchase agreement and transactions contemplated in this manner.

Durango Resources, Inc. (ATOXF), closed Wednesday's trading session at $0.044, even for the day. The average volume for the last 3 months is 4,063 and the stock's 52-week low/high is $0.037/$0.0777.

chart

Flexpoint Sensor Systems, Inc. (FLXT)

Equity Clock, Business Insider, The Street, Stockhouse, Simply Wall St, Investopedia, Investing, Tip Ranks, MarketWatch, Investors Hub, Uptick Newswire, Super Stock Screener, Research and Markets, Marketbeat, and Investor Place reported on Flexpoint Sensor Systems, Inc. (FLXT), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Flexpoint Sensor Systems, Inc. is a technology company specializing in developing products that feature its patented Bend Sensor® and related technology. The Bend Sensor's single-layer, thin film construction lessens costs and mechanical bulk. It does so while introducing a range of functions and stylistic design possibilities that have never before been available in sensing technology. Flexpoint Sensor Systems is based in Draper, Utah.

The Company produces the Bend Sensor® for manifold applications, covering many markets. These markets include automotive and transportation, wearables, medical, industrial controls, consumer products, and toys/gaming. Flexpoint Sensor Systems offers Consulting, Design, Development, and Manufacturing related to the adoption of the Bend Sensor® technology.

The Bend Sensor® product consists of a coated substrate, such as plastic, that changes in electrical conductivity as it is bent. Electronic systems connect to the sensor and measure with fine detail the amount of bending or movement that occurs. The single layer design of the Bend Sensor® eliminates many of the problems associated with conventional sensors, including dust, dirt, liquids, as well as heat and pressure effects.

Flexpoint Sensor Systems announced this past March that it received a Purchase Order from and entered into a Partner relationship with the Creative Interactions Lab (CIL) at Carleton University in Ottawa, Ontario. CIL is currently centering on researching deformable materials and flexible displays. Flexpoint Sensor Systems’ contributions to the collaborative relationship consist of its Bend Sensor® technology and engineering support.

CIL enables and empowers human computer interaction researchers to work on next generation interactions. CIL’s pioneering work marries novel interaction techniques with emerging user interfaces through software and hardware design, development and evaluation.

Since early in 2017, Flexpoint Sensor Systems and CaptoGlove® started a strategic, collaborative relationship to deliver unique, integrated virtual reality/augmented reality (VR/AR) systems driven by Bend Sensors® to mass markets. Flexpoint continues its wide-ranging success in the Virtual Reality/Augmented Reality (VR/AR) market for Glove-Based Systems.

Last month, Flexpoint Sensor Systems announced two major development opportunities.  These opportunities involve the implementation of two of the Company’s Bend Sensor® technologies for vehicles, and the development of its Bend® Sensor technology and its testing and proof of concept for tracking and monitoring the use of opioids.

Flexpoint Sensor Systems is working with two major U.S. Automotive manufacturers on its seat occupancy sensor technology and pedestrian impact sensor system. Moreover, the Company has been working and collaborating with another company to adapt and use the Bend Sensor® Technology in a system configuration, which will permit the healthcare industry to effectively track and monitor the usage of opioids on a real-time basis.

Flexpoint Sensor Systems, Inc. (FLXT), closed Wednesday's trading session at $0.06, up 20.00%, on 96,000 volume with 10 trades. The average volume for the last 3 months is 173,545 and the stock's 52-week low/high is $0.0322/$0.125.

chart

Teranga Gold Corporation (TGCDF)

StreetInsider, InvestorsHub, The Northern Miner, The Street, Stockhouse, OTC Markets, 4-Traders, Capital Equity Review, Simply Wall St, and 24hgold reported on Teranga Gold Corporation (TGCDF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Teranga Gold Corporation is a multi-jurisdictional West African gold company. Its emphasis is on production and development and the exploration of more than 6,400 km2 of land located on prospective gold belts. The Company is advancing its Wahgnion Gold Project, with a recently released positive feasibility study (FS), and conducting comprehensive exploration programs in Burkina Faso, Senegal and Côte d’Ivoire. Teranga Gold has its corporate office in Toronto, Ontario. The Company lists on the OTC Markets Group’s OTCQX.

Teranga Gold has almost 4.0 million ounces of gold reserves from its combined Sabodala Gold operations and Wahgnion Gold Project. Since its initial public offering (IPO) in 2010, the Company has produced greater than 1.4 million ounces of gold from its operations in Senegal, which as of June 30, 2017, had a reserve base of 2.7 million ounces of gold.

Teranga Gold owns and operates the Sabodala Gold mine. The Sabodala Gold mine is the only gold mine and mill in Senegal, West Africa.  The mine is roughly 650 km southeast of Dakar, the capital of Senegal.

Sabodala has been in operation since 2009. The Sabodala Mining Concession and the surrounding exploration permits are situated within the highly prospective Kedougou-Kenieba Inlier that forms part of the Paleoproterozoic age Birimian Terrane of the West African Craton.

In October of 2016, the Banfora Gold Project was acquired as part of Teranga’s acquisition of Gryphon Minerals. The fully permitted, high-grade, open pit Banfora Gold Project is in the southwest of Burkina Faso, West Africa in a major gold producing district host to a number of world class gold deposits. Teranga Gold owns 90 percent of the Project. The Burkina Faso government owns the remaining 10 percent.

Yesterday, Teranga Gold announced that it is acquiring the remaining 49 percent interest in the Golden Hill and Gourma projects from Boss Resources Limited for AUD10 million. Teranga earlier had the right to increase its 51 percent stake and earn up to an 80 percent interest in each project upon delivery of a feasibility study (FS) on either project and the payment of AUD2.5 million. With the transaction, Teranga Gold will own a 100 percent interest in each of the Golden Hill and Gourma projects in Burkina Faso, West Africa.

Teranga Gold Corporation (TGCDF), closed Wednesday's trading session at $2.93, down 5.18%, on 58,200 volume with 30 trades. The average volume for the last 3 months is 29,053 and the stock's 52-week low/high is $1.83/$4.325.

chart

Texas Mineral Resources Corp. (TMRC)

Stockrow, OTC Markets, InvestorsHub, and Marketwired reported on Texas Mineral Resources Corp. (TMRC), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Texas Mineral Resources Corp. is an exploration company headquartered in Sierra Blanca, Texas. It is targeting the heavy rare earths and an array of other high-value elements and industrial minerals. The Company’s emphasis is exploring and, if warranted, developing its Round Top heavy rare earth and industrial minerals project in Hudspeth County, Texas, 85 miles east of El Paso, Texas.

Incorporated in 1970, the Company formerly went by the name Texas Rare Earth Resources Corp. It changed its corporate name to Texas Mineral Resources Corp. in March of 2016. The Company lists on the OTCQB.

Last year, Texas Mineral Resources added a new strategic line of business with the establishment of a subsidiary called American Mineral Reclamation LLC. The establishment of this subsidiary is in response to the growing number of opportunities that the Company was presented due to work undertaken with partners, which resulted in winning grants from the Department of Defense (Defense Logistics Agency) and the Department of Energy.

Additionally, the Company’s plan is to develop alternative sources of strategic minerals through the processing of coal waste and other related materials. Its flagship property, Round Top Mountain, is near Sierra Blanca in Hudspeth County.

Round Top is one of four principal rhyolite bodies, an igneous volcanic rock, making up the group of mountains called The Sierra Blanca. The Preliminary Economic Assessment (PEA) was completed based on the measured, indicated and inferred Resource Estimate Technical Report filed on December 20, 2013 by Texas Rare Earth Resources.

The resource incorporated into the present mine plan totals 525.4 million kg of rare earth oxide (REO), with an average grade of 634 ppm total rare earth oxides (TREO). Of the TREO, about 72 percent consist of heavy rare earth oxides plus Yttrium. Texas Mineral Resources holds 19-year renewable leases from the State of Texas on 950 acres covering Round Top and additional prospecting permits on adjacent areas covering an additional 9,345 acres.

This past August, Texas Mineral Resources announced that its Round Top deposit contains all of the rare earth minerals required for the production of rare earth magnets as defined by the recently signed FY19 National Defense Authorization Act (NDAA). Signed into law on August 13, 2018, Section 871 of the NDAA specifically requires that all rare earth magnets and tungsten be melted or produced in nations other than China, Russia, Iran and North Korea. 

Texas Mineral Resources Corp. (TMRC), closed Wednesday's trading session at $0.18, up 5.88%, on 65,299 volume with 7 trades. The average volume for the last 3 months is 37,150 and the stock's 52-week low/high is $0.101/$0.349.

chart

Gratitude Health, Inc. (GRTD)

Cannabis Daily, Wallet Investor, Simply Wall St, MarketWatch, Investors Hangout, InvestorsHub, Morningstar, Stockhouse, Barchart, GuruFocus, and TradingView reported on Gratitude Health, Inc. (GRTD), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

Gratitude Health, Inc. manufactures, sells, and markets functional ready-to-drink (RTD) beverages under the Gratitude brand. The Company’s Founders, Mr. Roy Warren and Mr. Andy Schamisso, are beverage veterans with more than three decades of experience in the industry. Gratitude Health was conceived to manufacture healthy, unique, and certified-organic beverages for a consumer market interested in healthy aging. Established in 2017, Gratitude Health is based in North Palm Beach, Florida. The Company’s shares trade on the OTC Markets’ OTCQB.

Dragon Well tea (culturally known as "Longjing") comes from the pristine, certified-organic fields of Hangzhou China. Dragon Well tea has the distinction of being named "The Tea of Emperors". It is the most popular in China.

Gratitude Health offers flavored and unsweetened RTD teas. Its alternative food and beverage options are nutrient rich. They feature reduced or eliminated carbohydrate and sugar levels. Furthermore, they are full of anti-oxidants and organic ingredients. Each bottle contains no more than 45 calories. The Company’s 16 oz proprietary bottles feature collectible debossed designs intended to be reused and repurposed.

Gratitude Health pan-roasts its tea by hand. Its tea flavors include Dragon Well Green Tea Peach; Dragon Well Green Tea Mint; Dragon Well Green Tea Wildberry; Dragon Well Green Tea Blood Orange; and Dragon Well Green Tea Original. The Company’s routes to market include Direct-to-Retail sales; Direct Store Delivery (DSD); as well as Direct-to-Consumer sales via the Internet.

Gratitude Health announced earlier in 2018 that it entered into a definitive exchange and spinoff agreement with Vapir Enterprises, Inc., formerly traded under the symbol VAPI. The combination facilitated Gratitude Health, Inc. to become a publicly traded company.

With the agreement, Vapir Management retains its operations, intellectual property (IP), assets, and liabilities. It will continue as a separate operating entity and will not be involved in the beverage business.  Vapir is a developer and manufacturer of vaporization devices.

Today, Gratitude Health announced the launch of its initial line of products called Gratitude Dragon Well Green Teas.  The five-SKU line of ready-to-drink (RTD) Dragon Well Green Teas are all USDA-Certified Organic. They come in five distinct flavors. The line’s Peach, Wildberry, Blood Orange and Original flavors have 45-calories per 15-oz bottle. The fifth flavor, Mint, is a zero-calorie, unsweetened tea.

Gratitude Health, Inc. (GRTD), closed Wednesday's trading session at $0.066, up 32.00%, on 8,897 volume with 5 trades. The average volume for the last 3 months is 46,919 and the stock's 52-week low/high is $0.01/$0.785.

chart

Bespoke Extracts, Inc. (BSPK)

YCharts, Morningstar, Market Exclusive, Ventureline, Stockopedia, Investors Hangout, Wallet Investor, Infront Analytics, Simply Wall St, Stockhouse, Marketwired, MarketWatch, and Wallmine reported on Bespoke Extracts, Inc. (BSPK), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Bespoke Extracts, Inc. is a producer of high quality, flavorful, hemp-derived cannabidiol (CBD) extract products. The Company formed in early 2017 to introduce a proprietary line of premium quality, all-natural CBD products in the form of tinctures and capsules for the nutraceutical and veterinary markets. Bespoke Extracts has its corporate office in Sunny Isles Beach, Florida.

Today, Bespoke Extracts announced that its common stock was approved for up-listing to the OTCQB Venture Market Place, effective immediately. The OTCQB is a venture market. The design of this market is for early-stage and developing U.S. and international companies.

The Company’s products are produced using pure, all natural, zero-THC phytocannabinoid-rich (PCR) hemp-derived CBD. CBD is non-psychoactive.

Bespoke’s products are marketed as dietary supplements and distributed by way of the Company’s direct-to-consumers ecommerce store. Bespoke Extracts strives to use only vegan, Fair Trade Certified, and organic ingredients with fast acting benefits for anyone looking for an alternative remedy.

Bespoke Extracts’ emphasis is on premium ingredients. The Company’s farmers have been innovators in hemp agriculture, farming practices, agrotech, as well as production for generations. Bespoke’s hemp is stable, high in CBD, low in THC, and resistant to pests and pathogens.

The Company’s products include Sport Lemon Lime Tincture – THC Free 1500MG; CBD Manuka Honey Tincture; and CBD Bacon Flavored Pet Tincture. Products also include CBD Softgel Capsules; CBD Pain Relief Cream; and CBD Isolate Powder.

Earlier this month, Bespoke Extracts announced that it signed an agreement with Seidman Food Brokerage (SFB), providing for SFB to market Bespoke Extract’s proprietary CBD tinctures, lotions, and salves to over 1,500 stores located in Alabama, Florida, Georgia, North Carolina, South Carolina, Tennessee, The Bahamas and Puerto Rico.

Mr. Marc Yahr, President and Chief Executive Officer of Bespoke Extracts, said, “Our agreement with Seidman Food Brokerage marks a key inflection point in our go-to-market strategy and sets the stage for our achieving dynamic new revenue growth in our retail channel on a moving forward basis.  Given that Seidman is one of the industry’s most respected food brokerage firms, we take great pride in their decision to market Bespoke CBD products to their valued retail clients.”

Bespoke Extracts, Inc. (BSPK), closed Wednesday's trading session at $0.16, even for the day, on 230,647 volume with 55 trades. The average volume for the last 3 months is 282,106 and the stock's 52-week low/high is $0.105/$3.00.

chart

The QualityStocks Company Corner

Cyberfort Software, Inc. (CYBF)

The QualityStocks Daily Newsletter would like to spotlight Cyberfort Software, Inc. (OTC: CYBF).

Cyberfort Software (OTC: CYBF), a San Francisco, California-based cybersecurity technology company, is committed to its mission of delivering powerful cybersecurity solutions across multi-platforms for personal and business users. To view the full article, visit: http://nnw.fm/v7ayM.

Cyberfort Software, Inc. (CYBF) is a cybersecurity technology company specializing in the acquisition and development of security software, content filtering, and ad blocking technology. Headquartered in San Francisco, California, Cyberfort Software is actively dealing with various cyber threats through the development of innovative protection technologies designed for mobile, personal and business tech devices across multiple platforms.

Committed to the idea that everyone – from individuals to global corporations – should be able to enjoy a digital future free of malicious attacks robbing them of privacy and security, Cyberfort is working to strengthen its portfolio of cybersecurity IPs and stay one step ahead of cyberthreats. The growing plethora of tech devices enveloping everyday life opens the door to increasing cyberattacks through a stunning array of sophisticated cyberthreats. Protecting organizations and individuals with proactive security postures and protective measures is a key component of Cyberfort’s strategy to develop cybersecurity solutions that are smart, simple and efficient.

The company’s 2016 purchase of Vivio, a provider of pioneering AI content filtering and software protection, underscores Cyberfort’s commitment to cybersecurity. Vivio, an iOS 10 ad blocking app, currently serves over 10,000 unique users across iPhone, iPad and Mac. Vivio makes web browsing better, faster and more satisfying by blocking ads and reducing data usage, which also helps save battery life. Continuous ad blocking rule updates are delivered via an Intellectual Property Cloud-based autonomous engine with ad blocking tracker and malware detection filters.

Cyberfort recently signed a letter of intent to acquire Just Content Software which includes the Just Content app, software and underlying source code. Just Content is an efficacious and multi-functional ad blocking app that safeguards families and businesses with proprietary “Home Safe Filter” and “Business Filter” products. The Just Content app is available on iTunes and protects against unsafe links, adult content, phishing sites and inflammatory hate speech found on the internet, among other potential backdoor attacks and cyberthreats. A due diligence review is underway and a final determination regarding this acquisition is anticipated within weeks.

“Cyberfort aims to become a leader in developing cutting edge ad-blocking protective software that keeps the internet safe for families and business, which in our highly technological and immediate information-access society is a significant concern. Acquiring Just Content furthers our commitment to provide the best and most effective ad-blocking software in the marketplace,” says Cyberfort CEO Daniel Cattlin.

Favorable government regulations promoting tightened web security is a major factor driving adoption of web content filtering solution along with the public’s growing desire to better manage network bandwidth consumption and protect their online security and privacy. Cyberfort’s objective is to protect the data and integrity of personal and business computing assets and defend those assets against any threat or attack. The company’s software also offers symbiotic ad-blocking capabilities to complement its cyber defense effectiveness.

As Cyberfort continues to innovate, the Vivio team intends to leverage the current user base as a sandbox to test and optimize future incremental developments targeting an enterprise suite of tools that can be integrated into sector specific areas of growth. Key areas of focus include mobile device management, bring your own device (“BYOD”), mobile app management and secure mobile browser.

The Cyberfort leadership team is headlined by Cattlin, who offers a new age perspective to the business with expertise in project and asset management and a background in corporate finance. Cattlin brings both the operational and financial understanding to take companies from start-up and early development to expansion and capital growth within a public environment.

Chief Technology Officer Tomas Mistrik helped his team deliver a variety of technological products including the Vivio ad-blocking app for iOS 10 and the Silicon Valley-based Synergykit platform for mobile developers.

Technology Development Manager Krishna Kumar brings more than 10 years of experience in the Information Technology industry where he provided powerful security and ad-blocking measures for companies such as CSC and PayPal India.

Senior Advisor Harish Doddala brings nine years of product management and software engineering experience, delivering results for Cisco, VMware, Oracle, IBM and Siemens.

Cyberfort Software, Inc. (OTC: CYBF), closed the day's trading session at $0.25, up 35.14%, on 6,400 volume with 3 trades. The average volume for the last 3 months is 35,910 and the stock's 52-week low/high is $0.604/$2.23.

Recent News

chart

QMC Quantum Minerals Corp. (OTC: QMCQF) (TSX-V: QMC) (FSE: 3LQ)

The QualityStocks Daily Newsletter would like to spotlight QMC Quantum Minerals Corp. (QMCQF).

NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring QMC Quantum Minerals Corp. (OTC: QMCQF) (TSX.V: QMC) (FSE: 3LQ), a client of NNW engaged in the acquisition, exploration and development of natural resource properties containing high-quality lithium, silver, gold, nickel, copper and zinc mineralization. To view the full publication, titled “The Lithium Boom Has Only Just Begun,” visit: http://nnw.fm/zgLP1. Also today, NetworkNewsWire released a report on the company detailing how a once-developing lithium mining operation in southern Manitoba’s bountiful Cat Lake-Winnipeg River Pegmatite Field may soon be brought back to life by QMC Quantum Minerals, with prospects of establishing a new North America-based source of the in-demand metal.

QMC Quantum Minerals Corp. (OTC: QMCQF) (TSX-V: QMC) (FSE: 3LQ) is a British Columbia based company engaged in the business of acquisition, exploration and development of natural resource properties. QMC’s focus is on creating shareholder value through strategic acquisition and development of high quality lithium, silver, gold, nickel, copper and zinc prospects.

QMC’s current properties are in the Canadian province of Manitoba, one of Canada’s most productive, centrally located mining regions. These resources include the Irgon Lithium Mine project and two Volcanic Massive Sulphide (“VMS”) properties – the Rocky Lake and Rocky-Namew known collectively as the Namew Lake District Project – which contain base metal-rich mineral deposits. Excellent access and well-developed mining infrastructure to the company’s wholly-owned Irgon Lithium Mine Project offers significant value and ramps up the near-term production schedule, putting QMC in a position to take advantage of rising lithium prices.

The region’s historic resource estimate of lithium is well documented in a 1956 Assessment Report developed by a previous owner, Lithium Corporation of Canada Ltd. The project’s historical resource estimate of 1.2 million tons grading 1.51% lithium-oxide over a strike length of 365 meters and to a depth of 213 meters is being updated by QMC through a detailed channel sampling and subsequent drill program.

North Face Software Ltd. recently created an interactive 3-D model of the Irgon Dike utilizing all historical data derived from past drilling and underground work. The 3-D model clearly demonstrates that exploration and underground development has only taken place on the central portion of the dike, leaving significant potential to quickly increase tonnage.

The company’s latest assay results, obtained from 144 channel samples at QMC’s Irgon Lithium Mine Project, provided encouraging and positive results that compare favorably with the historic assays. QMC has received a drill permit from the Sustainable Development Office of the Manitoba government and is in the process of requesting and assessing bids from drilling contractors. The company plans to begin a 2,000-meter drill program to confirm the historic lithium oxide assay results documented in the historic 1953-54 drill program.

QMC’s experienced leadership team includes specialists in mineral exploration, geology, engineering, new business development, marketing and investor relations. The company’s team of qualified advisors includes consultant Bruce E. Goad, P.Geo., who has 40 years of experience in mineral exploration in Canada, Argentina, Asia and Africa. As a Qualified Person, Goad has worked on numerous deposit styles including rare element pegmatites, porphyry, banded iron formation (BIF) gold deposits, skarn, greisens,  and VMS. He has a wide and varied skill set which includes precious, base, industrial and rare metal projects with a sharp focus on gold exploration. Goad is the author of several scholarly publications on pegmatite granites of the southeastern Manitoba region.

The market for lithium has surged over the past three years with prices per metric ton tripling. The world’s rising demand for portable power can easily been seen in the electric vehicle and mobile device industries – both of which use lithium-based, renewable batteries as a power resource. QMC’s high potential prospects and experienced management team, both in geology and corporate finance, put QMC and its shareholders in an excellent position to take advantage of the lithium, precious and base metals markets.

QMC Quantum Minerals Corp. (QMCQF), closed the day's trading session at $0.2521, up 18.36%, on 384,005 volume with 76 trades. The average volume for the last 3 months is 104,882 and the stock's 52-week low/high is $0.129/$1.46.

Recent News

chart

Earth Science Tech, Inc. (ETST)

The QualityStocks Daily Newsletter would like to spotlight Earth Science Tech, Inc. (ETST).

Earth Science Tech, Inc. (OTCQB: ETST) (“ETST" or the “Company"), an innovative biotech company focused on the cannabidiol (CBD), nutraceutical and pharmaceutical fields, medical devices, and research and development, today provides an update on the progression of its cannabidiol (“CBD”) patents and reacts to the U.S. Drug Enforcement Agency’s (“DEA”) recent decision to remove certain CBD products from its Schedule 1 list of controlled substances. Also today, ETST was highlighted in an article discussing one of the more apparent emerging trends in the medical community is the increasing experimentation with CBD-based products and treatments as consumers are more open to alternative solutions to common diseases and ailments.

Earth Science Tech, Inc. (ETST) is an innovative biotechnology company operating in the fields of hemp cannabinoid (CBD), nutraceutical, pharmaceutical and medical device research and development. Earth Science Tech offers the highest purity and quality, full-spectrum, high-grade hemp CBD (cannabidiol) oil on the market. Made using the supercritical CO2 liquid extraction process, the company’s CBD oil is 100 percent natural and organic. Earth Science Tech has partnered with the University of Central Oklahoma and DV Biologics Laboratory to conduct research and development projects that scientifically support and advance the healthcare benefits of its high-grade hemp CBD oil.

Earth Science Tech Inc. currently has three wholly owned subsidiaries focused on developing its role as a world leader in the CBD space and expanding its work in the pharmaceutical and medical device sectors. These subsidiaries include:

  • Earth Science Pharma, Inc., which is committed to development of low cost, noninvasive diagnostic tools, medical devices, testing processes and vaccines for sexually transmitted infections and/or diseases. Earth Science Pharmaceutical CEO and chief science officer Michel Aubé is leading the company’s research and development efforts. The company’s first medical device, MSN-2, is a home kit designed for the detection of STIs, such as chlamydia, from a self-obtained gynecological specimen. Earth Science Pharma is working to develop and bring to market medical devices and vaccines that meet the specific needs of women.
  • Cannabis Therapeutics, Inc. (“CTI”), which is poised to take a leadership role in the development of new, leading-edge, cannabinoid-based pharmaceutical and nutraceutical products. CTI is invested in research and development to explore and harness the medicinal power of cannabidiol. The company holds a provisional application patent for a CBD product that is focused on developing treatments for breast and ovarian cancers.
  • KannaBidioiD (“KBD”) provides a wide variety of products geared toward the recreational space of cannabis. KBD’s unique Kanna and CBD formulation is sold and distributed in CBD-infused edibles and vapes/e-liquids products. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhanced focus and the added benefit of assisting with nicotine reduction therapy.

Earth Science Tech celebrated a significant, developmental year during 2017 by sharing its achievements in a condensed end-of-year report. Among the report’s highlights are the implementation of a development plan for the coming three years, which includes expanding into Canada and opening new manufacturing and shipping facilities. Of particular interest is the acquisition of Canna Inno Laboratories Inc., a company headquartered in Montreal, Quebec, Canada, which gives Earth Science Tech access to Canadian government grants offered to innovators in the pharmaceutical industry. ETST has also launched development of proprietary prophylactic therapies utilizing cannabidiol (CBD) to treat various forms of breast cancer.

In October 2017, ETST announced it is cooperating with the Clinique SIDA Amité (AIDS Friendship Clinic) for a mini-clinical trial, the last trial needed before the MSN-2 device, designed for the detection of STIs, enters molecular diagnostic trials. And in November 2017, the company began pre-launch human trials on a new CBD formula to fight against the U.S. opioid epidemic. The new formula, expected to decrease cravings and the negative effects of withdrawal in addicts, is based on industrial hemp CBD mixed with a known natural ingredient proven to help increase dopamine levels. ETST’s medical devices will first be launched in Vietnam, Djibouti and Morocco while the company awaits regulatory permission to enter the North American market.

The company expects to up-list to the OTCQB in early 2018, which management believes will attract well-funded institutional investors and pave the way to becoming the next billion-dollar-in-capitalization company on the OTC markets. Other highlights include completion of the company’s Scientific Advisory Council with a team of recognized scientists, the launching of several CBD-infused edible products and entry into the medical devices market through collaborative partnerships.

Earth Science Tech has signed a collaborate agreement with Laboratories BNK Canada, a private laboratory that will conduct the clinical studies necessary for MSN-2 medical device-related services to meet regulatory requirements. ETST has confirmed the MSN-2 device’s ability to detect chlamydia, and is working to validate similar results for gonorrhea, both highly infectious diseases that often have permanent consequences for patients. ETST will also add testing for trichomoniasis and a complete body fluid panel to detect the different serotypes of the human papillomavirus (HPV) that causes cervical cancer. These additions will help the company create sales opportunities in the global market for diagnostic testing of STDs that Transparency Market Research has indicated will grow to $108 billion by 2019.

Cannabis Therapeutics is in the development stage of two cannabinoid-based pharmaceutical drugs and three cannabinoid-based nutraceutical products targeting a variety of ailments such as anxiety, depression, triple negative breast cancer, and fatty liver disease, among others. Research into the benefits of the non-psychoactive cannabinoid molecules found in the cannabis plant is supported by ETST’s International Application for Provisional Patent titled “Cannabidiol Compositions Including Mixtures and Uses Thereof,” which was filed on October 8, 2015. Cannabis Thera’s R&D efforts are concentrated on developing CBD-based drugs and nutraceutical products and in working to integrate the CBD molecule with existing generic drug molecules to create more efficient medications with fewer and less severe side effects. A report in Hemp Business Journal predicts the CBD consumer market will grow to $2.1 billion by 2020, while other industry experts expect an increase to almost $3 billion by 2021. A recent report by Statista projects the U.S. consumer market for cannabinoid-based pharmaceuticals could reach $50 billion by the year 2029.

The management team at Earth Science Tech brings decades of invaluable experience to the nutraceutical, dietary supplement field as well as the life sciences sectors. Nickolas S. Tabraue, who serves as the president, director and chief operating officer, is an industry veteran with extensive knowledge of supplements, retail management, customer service and sales expertise. He is joined by CEO and CSO Dr. Michel Aubé, a microbiologist whose scientific research in sexually transmitted infections, cancer and stem cell biology has been widely published in several prestigious medical journals. Sergio Castillo, chief marketing officer, and Gabriel Aviles, chief sales officer, bring a wealth of marketing and sales experience to Earth Science Tech, which is complemented by Issa El-Cheikh, Ph.D., and his 25 years in the international finance, accounting, planning and execution of large scale transactions in the public and private sectors.

Earth Science Tech’s products include CBD, a natural constituent of hemp oil derived from hemp stalk and seed. EST offers CBD in the form of vitamins, minerals, herbs, botanicals, personal care products, homeopathies, functional foods and other products delivered in such forms as capsules, tablets, soft gels, chewables, liquids, creams, sprays, powders and whole herbs. Earth Science products can be found at retail stores throughout the United States and are available for purchase through the internet.

Earth Science Tech, Inc. (ETST), closed the day's trading session at $2.23, up 17.99%, on 804,109 volume with 905 trades. The average volume for the last 3 months is 58,137 and the stock's 52-week low/high is $0.421/$2.04.

Recent News

chart

FinCanna Capital Corp. (CSE: CALI) (OTCQB: FNNZF)

The QualityStocks Daily Newsletter would like to spotlight FinCanna Capital Corp. (FNNZF).

FinCanna Capital Corp. (CSE: CALI) (OTCQB: FNNZF) a royalty company for the U.S. licensed medical cannabis industry, is pleased to announce that its investee company Refined Resin Technologies Inc. (“Refined Resin”) of Oakland, California has acquired its second purchase order for THC distillate in the minimum amount of US$9.6 million.

FinCanna Capital Corp. (CSE: CALI) (OTCQB: FNNZF) is a royalty company aiming to be the capital partner of choice for high-growth, best-in-class businesses operating in the licensed U.S. medical cannabis industry. Primarily focused on the burgeoning California cannabis market, FinCanna leverages extensive investment expertise and industry experience to benefit its shareholders and portfolio companies.

Medical Cannabis Market

According to Ameri Research, the global market for licensed medical cannabis is growing at a compound annual growth rate (CAGR) of more than 21%, on track to exceed $63.5 billion by 2024. Within this market, FinCanna has identified considerable opportunity in California, the fifth largest economy in the world and the largest medical cannabis market in North America. Arcview Group forecasts California’s legal cannabis industry will grow at 21.1% CAGR to $6.5 billion in 2020, generating more than $1 billion in tax revenue.

Royalty Model & Portfolio

FinCanna’s “whole capital” solution for businesses in the licensed medical cannabis sector includes the provision of capital investment for a percentage of their future revenues. The FinCanna Capital Solution utilizes a royalty arrangement to deliver capital, in order to facilitate the growth or other specific objectives of its investees, and ensure the business opportunity is optimized. This model provides an alternative or complement to debt and equity financing, allowing investees to maintain financial flexibility and control of their business rather than entering into arrangements that may include restrictive debt structures or giving up an ownership stake.

FinCanna’s portfolio includes Cultivation Technologies, Inc. (“CTI”), a team of experts from Fortune 150 agriculture, medical cannabis, law, engineering and technology companies. FinCanna is providing funding to CTI for its planned, fully entitled, large-scale indoor medical cannabis facility to be developed in Coachella, California.

CTI has established an interim medical cannabis extraction facility (the “Interim Facility”) that will produce licensed medical cannabis products until the Coachella Project is complete. CTI is currently expanding its product line, Coachella Premium, to include vaporizer cartridges. Initial market feedback gathered during the product development phase indicates that Coachella Premium’s vaporizer cartridges offer a unique proposition within the vaporizer market, one of the fastest growing verticals in the cannabis market.

The Interim Facility can process up to 6,000 pounds of biomass per month, the equivalent of approximately 3.7 million grams of raw oil per year, with room for expansion. It is expected that the completed Coachella Project will be able to process 30,000 to 50,000 pounds of biomass per month, or the equivalent of 18 million grams to 30 million grams of raw oil per year.

Additionally FinCanna has entered into a royalty agreement with Green Compliance, a provider of point-of-sale software solution (“ezGreen”) for licensed medical cannabis dispensaries and cultivators. Green Compliance helps its customers comply with both the Health Insurance Portability and Accountability Act (“HIPAA”) and State Laws by ensuring patients’ confidential data is being handled properly, helping to protect from possible security breaches and financial and criminal liability resulting from potential violations.

FinCanna has also signed binding term sheet with Oakland, California-based Gram Co Holdings, subject to due diligence by FinCanna. Gram Co is a cannabinoid research and refinement facility focused providing B2B and B2C products and services to licensed medical dispensaries, infused product manufacturers, and numerous others in the cannabis supply chain. The company is also retrofitting a large, state-of-the-art medical cannabis extraction laboratory, which is expected to be operating in 2018.

The foregoing contains forward-looking statements regarding Cultivation Technologies Inc. (“CTI”) which are subject to risks, uncertainties and contingencies which include, but are not limited to the statements relating the future construction and completion of the CTI medical cannabis facility in Coachella, California, and the projected biomass processing and raw oil production at the facility. Such forward looking statements are based on assumptions regarding the construction, completion and operations of CTI’s proposed facility, including that CTI will obtain the financing required to build and equip its proposed facility, that CTI will obtain the additional financing required operate the facility, that construction facility is completed on time and budget, that CTI obtains state licenses to operate on a permanent basis, and that the equipment used in the cultivation of medical cannabis performs at scale in a similar way it performs at CTI’s pilot tests.

FinCanna Capital Corp. (FNNZF), closed the day's trading session at $0.2238, up 11.43%, on 86,655 volume with 37 trades. The average volume for the last 3 months is 43,214 and the stock's 52-week low/high is $0.10/$0.8736.

Recent News

chart

BriaCell Therapeutics Corp. (OTC: BCTXF) (TSX.V: BCT)

The QualityStocks Daily Newsletter would like to spotlight BriaCell Therapeutics Corp. (BCTXF).

NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring BriaCell Therapeutics Corp. (OTC: BCTXF) (TSX.V: BCT), a client of NNW focused on developing a targeted and safe approach to the management of cancer. To view the full publication, titled “Personalized Immunotherapy Could Be the Future for Advanced Breast Cancer Treatment,” visit: http://nnw.fm/Ixnq5.

BriaCell Therapeutics Corp. (OTC: BCTXF) (TSX.V: BCT), based in Berkeley, CA, and headquartered in Vancouver, British Columbia, is a clinical-stage biotechnology company focused on the development of targeted immunotherapy for advanced breast cancer.

BriaCell hopes to develop and market the first off-the-shelf personalized immunotherapy for the treatment of advanced breast cancer.

The results of two previous proof-of-concept clinical trials produced encouraging results in patients with advanced breast cancer. Most notably, one patient with breast cancer that had spread to other sites (metastatic cancer) responded to Bria-IMT™ with a substantial tumor shrinkage in multiple sites including the breast, the lung, soft tissues and even the brain. Similar observations have been confirmed more recently in additional patients, and BriaCell is developing BriaDX™ as a way to identify those patients most likely to respond.

BriaCell has recently completed recruitment of a Phase I/II study (NCT03066947) of Bria-IMT™, the Company’s lead product candidate, in advanced breast cancer patients showing an outstanding safety profile and excellent efficacy. BriaCell is currently enrolling advanced breast cancer patients in a combination therapy trial (NCT03328026) of Bria-IMT™ with Keytruda® (Keytruda® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.) or Yervoy® (Yervoy® is a registered trademark of Bristol-Myers Squibb Company). For further information on the Phase IIa clinical trials, please visit trial NCT03066947 and trial NCT03328026.

BriaCell’s pipeline also includes Bria-OTS™, the first off-the-shelf personalized immunotherapy for advanced breast cancer; and, a companion diagnostic product BriaDX™. By using BriaDX™ to identify and treat the patients who would most likely benefit from their immunotherapies, BriaCell expects to personalize the treatment for the patients, and bring hope to thousands of cancer patients who currently have few-to-no treatment options.

Breast Cancer Statistics

The National Cancer Institute estimates that more than 265,000 new cases of female breast cancer will be diagnosed in the U.S. during 2018, and that more than 40,000 women in the U.S. will die from the disease. Approximately 12 percent of women will be diagnosed with breast cancer at some point during their lifetime, based on 2013-2015 data.

Using its novel technology platform and strong R&D capabilities, BriaCell believes it has the opportunity to address this market, as well as have the opportunity to develop immunotherapy candidates for other cancer indications.

The global cancer immunotherapy market is expected to reach nearly USD$203 billion by 2025.

BriaCell Therapeutics Corp. (BCTXF), closed the day's trading session at $0.096, up 2.67%, on 81,560 volume with 12 trades. The average volume for the last 3 months is 14,009 and the stock's 52-week low/high is $0.068/$0.139.

Recent News

chart

Global Payout, Inc. (GOHE)

The QualityStocks Daily Newsletter would like to spotlight Global Payout, Inc. (GOHE).

Global Payout Inc. (OTCPink:GOHE) (“Global”) and its wholly owned subsidiary MTrac Tech Corp. (“MTrac” or the “Company”) are pleased to announce the execution of an exclusive agreement with Cultivate Technologies, LLC, a blockchain based Point of Sale company.  The deal allows MTrac to integrate Cultivate’s dynamic Point of Sale system into its existing blockchain powered payment processing platform.

Global Payout, Inc. (GOHE) provides comprehensive payment solutions that can be fully customized for virtually any domestic and international organization distributing money worldwide. The company is committed to enabling global access to technology for optimizing financial transactions and delivering a global financial eco-system with top-tier banking institutions and the highest level financial technology partnerships.

Today, more than ever before, commercial enterprises and government institutions need powerful financial technology solutions that have the flexibility to deliver innovative customer centric services and drive operational efficiency gains throughout the organization. The Global Reserve Platform is Global Payout’s fully configurable “banking-in-a-box” web-based platform that can fulfill the front-to-back office processing requirements of domestic, foreign exchange and international payment service providers. This platform is designed to improve work flow, operational efficiencies, and global financial management for enterprises operating across the globe.

The Global Reserve Platform can manage practically any financial product, including core and traditional banking products, online banking, card management, mobile wallets, merchant payment processing, biometric payments and authentication management, bill payments and P2P payments, international remittances, government benefits management, loans management, FOREX, and SWIFT / ACH / SEPA payments. Powered by the Global Reserve Administrative module, the platform can be customized for enterprises across a multitude of business sectors.

Investment in financial technology (FINTECH) companies has grown dramatically in recent years with the role of today’s banks shrinking and demand for improved financial solutions continuing to rise. As the industry has continued to expand rapidly, Global Payout’s management team has directed its focus on identifying the most promising market sectors with FINTECH needs. The four core areas selected are logistics, small and medium enterprises (SME), banking and travel.

In 2015, Global Payout introduced MoneyTrac Technology Inc. as a majority owned subsidiary to more effectively focus on the development of financial technologies that specifically address many of the challenges that enterprises in a variety of alternative and “high-risk” market sectors are faced with in processing financial transactions. Powered by Virtu Network Solutions, the MoneyTrac Technology platform is one the most configurable and intuitive financial technology platforms available to alternative and “high-risk” enterprises and provides them with solutions that effectively manages everything from pin debit and virtual currency, to compliance and cash flow logistics.

With the global economy constantly becoming more diversified and connected, Global Payout is well positioned with the technology software solutions its team has developed to address many different needs worldwide. Management has committed itself to exploring and identifying every avenue possible for further establishing itself as a recognized leader in FINTECH solutions.

Global Payout, Inc. (GOHE), closed the day's trading session at $0.0103, up 8.42%, on 4,856,668 volume with 130 trades. The average volume for the last 3 months is 5,250,498 and the stock's 52-week low/high is $0.0086/$0.159.

Recent News

chart

The Green Organic Dutchman (TSX: TGOD) (OTC: TGODF)

The QualityStocks Daily Newsletter would like to spotlight The Green Organic Dutchman (OTC: TGODF).

The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (OTCQX: TGODF) has attained a higher profile by adding well known investor and TV strategist Tim Seymour to its advisory board. TGOD was also highlighted by site The Motley Fool for its focus on alternative products. TGOD also described a private placement that would have gross receipts of up to $10 million.

The Green Organic Dutchman (TSX: TGOD) (OTC: TGODF), whose principal location is in Hamilton, Ontario, produces farm grown, organic, pesticide-free medical cannabis in small batches using all natural, organic craft growing principles. TGOD is licensed under the Access to Cannabis for Medical Purposes Regulations (ACMPR) to cultivate medical cannabis. The company carries out its principal activities producing cannabis pursuant to the provisions of the ACMPR and the Controlled Drugs and Substances Act (Canada).

Committed to becoming the global leader in delivering organic cannabis solutions that enhance people’s lives, TGOD consistently adheres to the highest levels of excellence. Its world-class management team includes a proven group of leaders with outstanding executive and operational experience specific to consumer packaged goods, consumer products, cannabis and finance industries.

TGOD is positioned as one of the highest quality and most cost efficient cannabis producers in Canada by leveraging innovative technology and low-cost power solutions. It holds one of the largest land packages under a single ACMPR license in Canada, providing future cannabis Agri-park style development and opportunities for joint ventures, licensing and distribution partners. Its industry leading alliance partners include Eaton, Ledcor Group and Hamilton Utilities Corp.

Eaton is the second largest power management company in the world and promises to supply innovative and cost effective power solutions to meet TGOD’s growing demands. Construction management is supplied by Ledcor, Canada’s second largest multidisciplinary construction company and a pioneer in the Green Building Industry. An alliance with Hamilton Utilities Corp allows TGOD to reduce its power costs from $0.13 per kWh to less than $0.05 per kWh. Greenhouse design is provided by Larssen Greenhouse, whose 25-plus years of experience in building some of the most modern and sophisticated greenhouses in the industry will provide TGOD with state of the art, climate-controlled hybrid greenhouse solutions.

Canada is quickly becoming a hub for cannabis investors with over $1.3 billion raised by Canadian companies to date. There are 58 licensed producers to service a population of 36 million and only two organic producers. TGOD, which holds licenses in Ontario and Quebec, is strategically located in both provinces that together claim 22 million Canadians as residents. Another estimated 57 million people live next door in six U.S. bordering states.

The Canadian cannabis market currently has a massive supply demand gap, which makes TGOD’s expansion plans even more important to investors. These plans include a combined build-out capacity of 970,000 square feet, allowing TGOD to produce 116,000 kg annually of organic cannabis. Upon completion, Phase One in Hamilton, Ontario, which is fully funded, will provide 150,000 square feet of growing capacity capable of producing up to 14,000 kg of cannabis or $112 million in revenue at $8 a gram.

The company’s Quebec expansion will be constructed on a recently secured 75-acre property near Montreal. This new property has a planned expansion of 820,000 square feet capable of producing 102,000 kg of organic cannabis. The first phase of this expansion is underway and construction is expected to be completed by the end of 2018. Quebec’s first phase will consist of 220,000 square feet capable of producing 22,000 kg of cannabis. Two additional expansion phases will add 250,000 square feet (26,000 kg of cannabis) and 350,000 square feet (54,000 kg of cannabis). Power costs remain exceptionally low for both facilities with access to all other needed utilities available and close by.

TGOD also plans to gain a share of the burgeoning cannabis oils market which by Q1 2017 accounted for 49 percent of all cannabis sold in Canada under the ACMPR, up from only 27% in Q2 2016. TGOD has ordered a purpose-built extraction laboratory with an estimated commission in Q4 of 2017. This is a commercial-scale CO2 extraction unit capable of processing up to 12,000 kg of raw material per year and producing approximately $170 million worth of organic cannabis oils. Raw cannabis oil provides a significant downstream manufacturing opportunity into several potential recreational market verticals including edibles, beverages, topicals and concentrates.

Data from the Canadian ACMPR Market Trends report indicates a rising number of consumers will continue to seek out healthier, less conspicuous ways to consume cannabis, ensuring sales of organic cannabis oil products remain brisk. Organic cannabis products demand a significant premium compared to non-organic products and the demand keeps growing.

Plans to take the company public are underway with an initial public offering (IPO) slated for January 2018. In November, the company raised $13 million in equity financing and in March closed a $27 million non-brokered private placement. Another $20 million is currently being raised before the IPO in January, which will be utilized for expansion plans.

TGOD is uniquely positioned between the medical and recreational cannabis industry since Canada is scheduled to legalize cannabis for all adults in mid-2018. As of August 2017, TGOD has 2,400 shareholders. Established in 2012, TGOD’s motto, “Making Life Better,” can be seen in its strategic partnerships, top quality management team, and dedication to organic farming and principles.

To learn more about the company and how to invest, contact TGOD directly at financing@tgod.ca

The Green Organic Dutchman (OTC: TGODF), closed the day's trading session at $4.86049, up 3.86%, on 864,116 volume with 2,386 trades. The average volume for the last 3 months is 878,290 and the stock's 52-week low/high is $2.784/$7.894.

Recent News

chart

Pressure BioSciences Inc. (PBIO)

The QualityStocks Daily Newsletter would like to spotlight Pressure BioSciences Inc. (PBIO).

Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide life sciences industry, today announced it will commit significant additional financial and operational support to accelerate the development of its Ultra Shear Technology ("UST") platform, effective immediately.

Pressure BioSciences Inc. (PBIO) develops, markets and sells proprietary laboratory instrumentation and associated consumables to the life sciences sample preparation market. Sample preparation refers to the wide range of activities that precede most forms of scientific analysis. It is often complex and time-consuming, yet a critical part of scientific research. The market for sample preparation products is currently estimated at $6 billion worldwide.

The Company’s product line can be used to exquisitely control the sample preparation process. It is based on a patented, enabling technology platform called pressure cycling technology (“PCT”). PCT uses alternating cycles of hydrostatic pressure between ambient (14.5 psi) and ultra-high levels (up to 100,000 psi) to safely and reproducibly control critical biological processes, such as the lysis (breakage) of cells, the digestion of proteins, and the inactivation of pathogens.

Pressure BioSciences’ product line is led by its newly released, next-generation Barocycler 2320EXTREME instrument. Named a finalist in the prestigious 2017 R&D Awards (also known as the “Oscars of Innovation”), the Barocycler 2320EXT is already being touted by some key opinion leaders as an essential element of the $1.8 billion U.S. “Cancer Moonshot” program. For example, Professor Phil Robinson, Co-head of the cancer research center of the Children’s Medical Research Institute (Sydney, Australia), said in a recent interview: “We are collecting the whole proteome on 70,000 tumor samples from all classes where complete clinical outcome is known. Due to its unique capabilities, the Barocycler 2320EXT has become a critical part of our program. It is the primary enabler of the high-throughput component of the project. Without this step, our project simply could not be done. In fact, the Barocycler 2320EXT works so well we have just purchased two more.”

Momentum is building when it comes to the potential for using the Company’s unique PCT technology platform. Leading scientists are intrigued by Pressure BioSciences’ approach, which among other attributes, revolutionizes the process of rupturing cells (lysis) for further study, yielding superior biomolecules for investigation. The Company’s technology transcends current methods of breaking open cells, which use chemicals, blades, metal beads, or other damaging and altering methods that can ultimately adversely affect the result for researchers. Pressure BioSciences’ PCT technology utilizes customized, controlled hydrostatic (water) pressure to rupture cells in a chamber, enabling exquisitely customized levels of pressure to optimally break open different types of cells at prescribed pressure levels—something never before accomplished in a commercial setting. Using this pioneering method, the result is a truer, more legitimate sample, which boosts the efficacy of research and the quality of results. The potential impact of this technology on scientific advancement is enormous, enabling research scientists to begin their studies with biological samples of unprecedented integrity, with the potential to improve research outcomes at the earliest, most critical step. PCT can additionally inactivate pathogens (e.g., viruses, bacteria) using hydrostatic pressure, making the samples safer to study—another innovation with astronomical potential for application in a variety of markets.

The Company’s high-pressure instruments for research purposes are marketed throughout the United States, Europe, China and Japan. To date, Pressure BioSciences has installed nearly 300 PCT Systems in over 165 leading academic, government, biotech and pharma laboratories around the world. Its primary applications are in biomarker discovery, forensics, agriculture and pathology. Over 100 scientific papers have been published on the advantages of the PCT platform, which is also being used in the specialized fields of drug discovery and design, bio-therapeutics characterization, soil and plant biology, vaccine development and histology.

Impressive as their biotech business is, there is more to the PBI story. Pressure BioSciences recently received two patents in China for its novel Ultra Shear Technology (UST), a process that has potential in a wide range of industrial applications, including extending the shelf life of some food products and making two insoluble liquids (like oil in water) soluble. Patents have also been filed in many other countries worldwide. UST is a novel technique based on the use of intense shear forces generated from ultra-high-pressure valve discharge.

This important technology has the potential to play a significant role in a number of commercially important areas through its ability to create high-quality, stable nanoemulsions. Scientific studies indicate that improved absorption, higher bioavailability, greater stability, lower surfactant levels and other advantages can be achieved with nanoemulsions – all hugely important factors in the fields of nutraceuticals, cosmetics, pharmaceuticals, and in various medical products. There is an enormous opportunity in the cannabis market, since the technology can potentially reduce oil droplets containing cannabidiol (CBD) to nanoparticles, after which they can be safely suspended in a stable water solution—something many companies have endeavored to achieve without success. Researchers looking for a way to increase the bioavailability of cannabinoids in the body will find this technology a game changer.

The Company’s UST technology also has possibilities in the production of clean label foods, which are currently processed using several innovative methods, including high-pressure treatments (such as Starbucks’ Evolution line of juices). In 2015, the worldwide market for high-pressure processed (HPP) food was estimated at U.S. $10 billion. UST uses ultra-high pressures and certain valves to generate intense shear forces under controlled temperature conditions to produce nanoemulsions, and which also significantly reduces food-borne pathogens. Pressure BioSciences’ initial focus with this technology will be to evaluate UST for the production of high-quality dairy products and beverages.

Pressure BioSciences Inc. (PBIO), closed the day's trading session at $3.60, even for the day, on 701 volume with 5 trades. The average volume for the last 3 months is 2,010 and the stock's 52-week low/high is $2.70/$5.00.

Recent News

chart

VIVO Cannabis Inc. (TSX.V: VIVO) (OTC: VVCIF)

The QualityStocks Daily Newsletter would like to spotlight VIVO Cannabis Inc. (VVCIF).

VIVO Cannabis Inc. (TSXV: VIVO, OTCQX: VVCIF) (“VIVO” or the “Company”) is pleased to announce that it has made a $5 million strategic investment in Westleaf Cannabis Inc. (“Westleaf”), which is intended to be used by Westleaf to advance the roll out of their cannabis retail operations across Canada. Westleaf’s mission is to provide a sophisticated and differentiated approach to customer engagement, appealing to customers through music and cannabis culture.

VIVO Cannabis Inc. (TSX.V: VIVO) (OTC: VVCIF) is a globally licensed, cost efficient producer of premium quality, organic, standardized medicinal cannabis. One of the earliest licensed medical marijuana producers under Canada’s federally-controlled Access to Cannabis for Medical Purposes Regulations (ACMPR), VIVO has five years of operating experience in the burgeoning medical marijuana space through its flagship operation, ABcann Medicinals, Inc. The company recently received its Health Canada license to produce medical cannabis oils and is working toward production of saleable, extracted, finished products that will lead to a final inspection allowing sales of its oils.

“Receipt of the license to produce cannabis oils is a major milestone in our pursuit to provide our medical cannabis patients with additional product formats that can be precisely dosed. The expansion and innovation of our product lines are a top priority for the Company as we continue to serve the needs of our customers, and we anticipate strong demand for our cannabis oil products,” VIVO CEO Barry Fishman said.

VIVO owns and operates a fully functioning 14,500 square foot facility in Napanee, Ontario, which is being doubled in size to produce 1,400 kg of cannabis per year. The company’s expansion plans include adding a seasonal greenhouse and a hybrid, multipurpose facility, capable of producing 31,000 kg of cannabis per year between the two facilities, to be constructed on 65 acres it already owns near the Napanee facility. This additional location is properly zoned with existing infrastructure in place for an eventual 1.2 million square feet of production space.

VIVO has built a reputation over the years for its best-in-class standardized approach to growing cannabis that includes the absence of pesticides and a computer monitored growing technique that provides a consistent, pharmaceutical-grade with high yields. The company’s custom, scalable growing chambers with proprietary lighting can be replicated anywhere in the world, leading to lower production costs. This technique has helped it record a customer retention rate of 94.7 percent alongside 30 percent month-over-month customer growth. When combined with VIVO’s current yield rate, which it has measured at roughly 100 percent greater than the industry average, the company has constructed a strong foundation upon which to build a sizable presence in the global cannabis industry.

This global growth potential is illustrated by VIVO’s partnership with Israel’s Syqe Medical, producer of the world’s first selective-dose pharmaceutical grade medicinal plant inhaler. After visiting VIVO’s production facility, Perry Davidson, founder of Syqe Medical, noted that the company’s production technologies put it “in a class with the best in the world” in its ability to produce standardized pharmaceutical grade cannabis.

VIVO’s recent acquisition of Harvest Medicine Inc. represents further progress toward the company’s goal of becoming a vertically integrated medical cannabis company. Harvest Medicine is one of the fastest growing medical cannabis clinics in Canada – adding over 1,200 new patients monthly from a single location – with an aggressive expansion plan and a patient-focused approach that perfectly aligns with VIVO’s philosophy of quality and innovation.

VIVO’s seasoned management team, board of directors and advisory board features well over a century of combined industry experience. Fishman, who has over 20 years of experience as a business leader, previously served as CEO of both Teva Canada and Taro Canada, as vice president of marketing at Eli Lilly Canada, and as past chair of the Canadian Generic Manufacturers Association. He most recently served as CEO of international specialty pharmaceutical company Merus Labs.

Notably, VIVO also has access to the ‘Father of Cannabis Research’, Raphael Mechoulam, PhD, through its board of advisors. An organic chemist and professor of medicinal chemistry at the Hebrew University of Jerusalem, Mechoulam was the first scientist to isolate both cannabidiol (CBD) and tetrahydrocannabinol (THC). He has received more than 25 prestigious academic awards, including the Rothschild Prize in Chemical Sciences and Physical Sciences in 2012.

With more than 65 acres of growth capacity, a healthy cash balance to fund upcoming construction efforts, steady sales growth, industry-leading yield rates and an established operations team in place, VIVO is well positioned to compete in the rapidly expanding Canadian cannabis industry and beyond.

VIVO Cannabis Inc. (VVCIF), closed the day's trading session at $1.13, up 1.09%, on 688,959 volume with 842 trades. The average volume for the last 3 months is 648,450 and the stock's 52-week low/high is $0.73/$3.29.

Recent News

chart

Sharing Services, Inc. (SHRV)

The QualityStocks Daily Newsletter would like to spotlight Sharing Services, Inc. (SHRV).

Sharing Services, Inc. (OTCQB: SHRV) (“the Company”) announces it has retained the services of Larry Thompson as its business strategist, effective immediately. Mr. Thompson, founder of global strategy firm LT Wealth Building Academy, will be advising on the launch of Elepreneurs 2.0, debuting in November 2018.

Sharing Services, Inc. (SHRV), headquartered in Plano, Texas, is a diversified holdings company focused on reshaping how entrepreneurs succeed today. Sharing Services Inc. owns, operates or controls an interest in a variety of companies specializing in the direct selling industry that either sell products to the consumer directly through independent representatives or offer services that range from health and wellness, energy, technology, insurance services, training, media and travel benefits. SHRV has created the “Blue Ocean Strategy,” which melds three keys together to implement the company’s vision. These keys include elevating home-based entrepreneurs, known as “Elepreneurs,” utilizing the direct selling channel to generate 100 percent organic growth.

Sharing Services Inc. subsidiaries include:

  • A growing international network of home-based entrepreneurs, called “Elepreneurs”
  • Growing selection of health and wellness products dedicated to elevating the well-being of all people
  • Insurance from auto, home and life to health benefit discounts and health insurance that help families elevate their options
  • Wholesale travel and payment programs with travel concierges that empower more families to go on vacation
  • Live seminars and training events – from Vacationars™ to EduTainment – that elevate the skills and knowledge of entrepreneurs around the world
  • Unique compensation and reward programs crafted to help entrepreneurs elevate their health, wealth and happiness

Sharing Services recently expanded its corporate footprint by moving to a 10,000 square foot facility in Plano, Texas, that offers room to expand as the company grows and its subsidiaries flourish. The larger corporate locale provides space for a growing customer service department, product fulfillment, opportunity and training rooms, as well as a video production suite.

“The opportunity to expand to the rest of this new building over the course of the next six to 12 months ensures we won’t have to move again anytime soon,” Sharing Services Inc. Chairman Robert Oblon said. “We are on track for very significant growth here in the U.S., as well as upcoming international expansion, so this move is in preparation for what’s in front of us.”

The company recently signed a joint venture agreement with Health Wealth & Happiness Limited (“HWH”) to expand its “Elepreneurs” brand and market its products throughout Asia. The newly formed company will be named “Elepreneurs Asia Limited” and will have marketing and sales rights to China, Hong Kong, Macau, South Korea, Japan, Taiwan, Cambodia, Indonesia, Laos, Malaysia, the Philippines, Singapore, Thailand, Vietnam and Papua, New Guinea. A soft launch of the Elepreneur program is scheduled sometime later in 2018 with HWH CEP Fai Chan and his team leading the effort. Formed in Hong Kong, Health Wealth & Happiness Limited is dedicated to working with visionary partners like Sharing Services Inc. to deliver the best products and services to improve the well-being of consumers.

Nearly 1,000 people attended Sharing Services, Inc.’s first “Elepreneur Happiness Convention,” held March 2-3, 2018, in Dallas, Texas. Attendees arrived from several countries including the U.S., Canada, Mexico, Singapore and Hong Kong. Keynote speakers included several internationally known motivational leaders – Shawn Achor, Sandra Yancey, John Fleming and Les Brown – who provided exceptional material and inspirational discussion points.

“The enthusiasm of our attendees and the early success that we are experiencing is incredible considering our growth has been 100 percent organic, with almost no marketing from the company,” Oblon said. “I’m speechless by the dedication of our Elepreneur leaders and their entire teams, as they share our incredible line of products that have helped so many people.”

Sharing Services and its management team plan to travel the U.S. to hold several mini conferences to expand on the messages presented at its Happiness Convention that focus on helping people become “healthier, happier and wealthier.” Details of the company’s aggressive global expansion initiatives are soon to be announced, Oblon said.

The law firm of Gardere Wynne Sewell LLP has been retained as outside corporate counsel for all general business matters. The Dallas-based law firm will represent Sharing Services, Inc., and its subsidiaries as the company utilizes the direct selling channel for a significant component of its overall growth strategy.

John “JT” Thatchwas appointed president and chief executive officer of Sharing Services, Inc., at a March 1, 2018, annual shareholder meeting. Thatch has successfully started, owned and operated several sized businesses in various industries. His experience with corporate growth, acquisitions, financing and negotiation in fast-paced and flexible environments will significantly assist Sharing Services Inc. as the company aims to expand and increase revenues.

Sharing Services, Inc. (SHRV), closed the day's trading session at $0.25, even for the day, on 1,000 volume with 2 trades. The average volume for the last 3 months is 15,233 and the stock's 52-week low/high is $0.125/$0.729.

Recent News

chart

The Flowr Corporation (TSX.V: FLWR)

The QualityStocks Daily Newsletter would like to spotlight The Flowr Corporation (FLWR).

The Flowr Corporation (TSX.V: FLWR), a Canadian cultivator of premium cannabis, this morning announced a strategic partnership with Ace Valley, a new brand of cannabis products targeted at the upcoming Canadian adult-use recreational market. To view the full press release, visit: http://nnw.fm/gAl2h. Also today, NetworkNewsWire released a report on the company detailing how FLWR was the subject of an article published by TheGlobeandMail.com. To view the full press release, visit: http://nnw.fm/S3jor.

The Flowr Corporation (TSX.V: FLWR), a Health Canada Licensed Producer (LP) of cannabis under the Access to Cannabis for Medical Purposes Regulations (ACMPR), is an emerging Canadian cannabis leader founded by Medreleaf co-founder Tom Flow and a team of industry pioneers, successful start-up executives and top industry scientists. Flowr’s purpose-built cultivation facilities may be the most advanced in the industry, consistently generating high crop yields, delivering premium and ultra-premium cannabis products, and maximizing return on investment. The company also may be an R&D leader as it was selected by the Hawthorne Gardening Division of The Scotts Miracle-Gro Company as its exclusive Canadian cannabis R&D partner.

Flowr’s flagship facility, an 84,000-square-foot campus on seven acres in Kelowna, British Columbia, is engineered to grow premium cannabis in rooms that meet pharmaceutical industry production standards for cleanliness. This, along with exacting protocols designed by the Flowr team, enables Flowr to grow cannabis that meets Health Canada’s stringent standards without treating it with the taste- and smell-killing gamma irradiation that most other producers have to use to clean their product. Irradiating the plant – a process similar to pasteurizing food – impairs many of the important terpenes that provide the positive effects, flavors and scents of cannabis while strengthening unpleasant terpenes. Flowr’s products may deliver a better user experience, thus commanding premium prices.

Flowr’s cultivation facilities, built with proprietary, patent-pending systems, are designed to deliver yields targeted at 450 grams per square foot by the end of 2022, which is three times more efficient than the industry average of approximately 150 grams per square foot. By optimizing yield, the Company may produce significantly more cannabis flower on a smaller footprint than other producers, thus generating far high revenue per square foot and keeping costs much lower, leading to higher margins. The Kelowna facility is presently 20 percent operational with the remaining 80 percent slated to come online by early 2019. It is expected to produce up to 14,000 kg of premium, non-irradiated cannabis flower in 2019. With further enhanced yields and planned expansion of production facilities on the campus, Flowr will reach a total capacity of 60,000 kg annually in 2022.

Leading Flowr’s cultivation program is industry pioneer, company co-founder and Flowr president Tom Flow. Flow is widely recognized for his cannabis thought leadership and expertise building and operating cannabis cultivation facilities. Flow also co-founded MedReleaf and designed, built and set up SOPs for their flagship Marcum cultivation facility. Marcum has continued to be perhaps the most productive facility in the country prior to the Flowr flagship facility. Long one of Canada’s most efficient and profitable LPs, MedReleaf was acquired by Aurora for approximately C$3 billion. Flow and his team have designed and built a total of 17 cultivation facilities and secured three producer’s licenses under various Canadian regulatory regimes.

In March 2018, Flowr and the Hawthorne Gardening Division of The Scotts Miracle-Gro Company – a world leader in lawn and garden products – announced an exclusive strategic R&D alliance. After evaluating numerous Canadian LPs, Hawthorne chose to partner with Flowr based on the experience and expertise of the company’s cultivation and R&D teams and the company’s advanced growing capabilities.

Hawthorne will fund the construction of a 50,000-square-foot R&D facility that is integrated into Flowr’s Kelowna campus. This facility is North America’s first dedicated cannabis R&D facility focused on advancing cultivation techniques and systems. The facility will support researchers from both organizations and combine laboratories, indoor and greenhouse grow suites, training areas and genetics breeding areas in a single building. It is expected to open in early 2019. In addition to helping Flowr maintain its competitive advantage in cultivation, the company’s R&D program will keep it on the cutting edge of cannabis innovation.

Flowr is entering the market with three different brands to meet the growing demand for premium, non-irradiated cannabis in the medicinal and adult use markets:

  • FlowrRx, featuring premium quality medicinal cannabis that enables patients to live better, fuller lives. A dedicated Client Services team will provide patients with personalized support while an R&D team develops innovative flower strains and premium products targeted to specific conditions. Patient well-being is considered at every stage of the process – from genetic selection to harvest, trimming and curing techniques. FlowrRx and its team of passionate scientists and leading cultivation specialists are dedicated to advancing the scientific understanding of cannabis.
  • Flowr is the company’s premium recreational adult-use brand featuring an active, West Coast-inspired lifestyle for the cannabis connoisseur and enthusiast market. Through the continuous innovation of procedures and practices, Flowr’s talented team of experts is crafting premium products that deliver unparalleled experiences.
  • Ace Valley, an exclusive partnership with top-selling Ontario craft beer company Ace Hill, will bring Flowr’s premium product to the millennial and casual adult-use markets under the Ace Valley brand.

Flowr recently signed a Memorandum of Understanding with the British Columbia Liquor Distribution Branch, the province’s sole legal wholesaler of non-medical cannabis, to supply premium and ultra-premium flower to the province’s retail outlets. The company has agreements with several major medical distributors and is in discussions about retail distribution with additional provinces where it believes it can obtain prices commensurate with the quality of the Flowr products. The company is also evaluating other market opportunities including export.

Flowr is poised to become the pre-eminent indoor premium cannabis grower in Canada and one of the country’s top five LPs. The company’s focus on yield, quality and price point and its team’s ability to grow at scale should drive high margins, significant growth and strong return on investment.

The Flowr Corporation (TSX.V: FLWR), closed the day's trading session at $6.00, off by 2.60%, on 294,851 volume with 400 trades. The average volume for the last 3 months is 240,589 and the stock's 52-week low/high is $4.00/$8.00.

Recent News

chart

Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (LXRP).

CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article discussing Lexaria Biosciences Inc. (CSE: LXX) (LXX: CN) (CNSX: LXX) (OTCQX: LXRP). The company has developed an innovative drug delivery platform that increases intestinal absorption rates, rapidly delivers active ingredients to the bloodstream, and provides taste-masking benefits.

Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP) has developed and out-licenses its proprietary technology for improved taste, rapidity, and delivery of bioactive compounds, including cannabinoids. Though boasting a wide range of health benefits, cannabinoids are traditionally poorly absorbed by the body’s gastrointestinal tract. To achieve higher effectiveness, consumers usually default to smoking. Lexaria provides a superior administration method by delivering hemp oil ingredients – or through locally licensed partners, cannabis oil ingredients – through a patented process within food products.

The key differentiator between Lexaria’s products and others on the market is the company’s disruptive technology proven to enhance the absorption of orally ingested cannabinoids while improving the “unusual” taste of cannabinoids and allowing for lower overall dosing with higher efficacy. Lexaria is primarily a B2B enterprise, and is in licensing discussions or has existing agreements with companies in Canada, the largest-market states in the USA, and internationally. Lexaria has also developed its own brands partly for demonstration purposes, utilizing its patented technology to infuse hemp oil ingredients within lipids in popular foods. These brands include ViPova™, Lexaria Energy Foods, and TurboCBD™.

In 2015, Lexaria commissioned an independent, third-party lab to test its technology under carefully monitored in vitro conditions. Results showed that the company’s technological process and lipid formulation both improve intestinal absorption as much as 500%. Additional follow-up studies in human volunteers suggested that Lexaria’s processed, lipid-infused tea may be more effective in an actual gastrointestinal system than in an in vitro simulation with results indicating as much as a 1,000% increase in overall absorption.

Lexaria also has an R&D partnership with the Canadian government’s National Research Council. That R&D is expected to characterize molecular bond formation theorized to occur with Lexaria’s unique technology between the lipid delivery agents and the bioactive substances it processes and combines. Results from this R&D are expected to support accelerating B2B relationships – not just in the cannabis industry, but also to support new B2B business relationships in the fields of vitamins, NSAIDs, and nicotine delivery. All of these sectors expected to offer additional future growth potential.

Aside from testing, a critical component of Lexaria Bioscience’s business model is a strong intellectual property portfolio that utilizes the most commonly used food processing techniques. As of 2017, the company’s patent portfolio includes 19 patent applications filed and pending in more than 40 countries around the world. The most recent patent applications expand Lexaria’s lipophilic food and beverage composition claims to include the processing of cannabinoids, vitamins, NSAIDs and nicotine in many of the world’s most commonly used food processing ingredients. Lexaria is expecting additional new patent awards both in the USA and internationally in 2017 and 2018.

Royalties play a vital role in Lexaria’s revenue-generating business model. The company out-licenses its technology (royalty) to third party partners, and has several deals signed and/or pending. The company’s growth initiatives are guided by a management team headed by CEO Chris Bunka, a serial entrepreneur who has raised more than $50 million in working capital for the companies he has led over the course of his career. He is supported by a team of professionals with extensive experience in pharmaceutical and bioscience sectors, invention, toxicology, consumer goods, and other relevant skillsets.

Lexaria Bioscience Corp. (LXRP), closed the day's trading session at $1.7995, off by 2.73%, on 211,547 volume with 261 trades. The average volume for the last 3 months is 201,812 and the stock's 52-week low/high is $0.322/$2.54.

Recent News

chart

Golden Developing Solutions, Inc. (DVLP)

The QualityStocks Daily Newsletter would like to spotlight Golden Developing Solutions, Inc. (DVLP).

Golden Developing Solutions, Inc. (OTCMKTS: DVLP) (“DVLP” or the “Company”), an emerging leader in the Cannabis and CBD marketplace, is proud to announce extremely robust user activity data in the “Pre-Purchase App” associated with its newly acquired subsidiary, Where’s Weed (wheresweed.com), an online and mobile cannabis services hub that focuses on fast, secure, and efficient discovery and purchasing of cannabis in both recreational and medical cannabis markets in the United States and Canada. Also today, NetworkNewsWire released a report on the company detailing how DVLP is “One to Watch.”

Golden Developing Solutions, Inc. (DVLP), an emerging leader in ancillary software and the cannabidiol (CBD) products marketplace, provides business services and/or products supporting the cannabis industry including an online retail business for CBD, hemp oil and health/wellness related products.

Global acceptance of cannabis and related CBD products continues to increase as North America advances toward favorable legislation. Canada is set to legalize recreational cannabis in October 2018, and the United States has 30 states and the District of Columbia allowing either recreational or medical cannabis, or both. Voters in four additional U.S. states will consider marijuana initiatives on the November 2018 ballot. The global legal cannabis market is projected to reach USD$146 billion by the end of 2025, with a greater acceptance of medical cannabis products as a driving factor, according to Grand View Research.

DVLP is taking advantage of consumer demand for CBD products through its wholly owned Pura Vida Vitamins, LLC subsidiary, which recently launched a direct-to-consumer website (www.PuraVidaVitamins.com) and commenced sales of Pura Vida branded products. Pura Vida merchandise includes hemp and CBD-related products and other products focusing on health and lifestyle which are available through established wholesale and distribution channels. In addition, a line of CBD pet supplements and other products are in development.

DVLP recently acquired “Where’s Weed” (Layer Six Media LLC DBA “Where’s Weed”) and its primary asset,?WheresWeed.com. Where’s Weed is an American cannabis technology company known for connecting medical and recreational cannabis users with trusted local marijuana businesses in their communities. As a rapidly growing community-based online resource for cannabis consumers with a host of user-friendly services, Where’s Weed offers a sophisticated mobile app with strong traction and powerful growth potential as the North American legal cannabis market continues to expand exponentially.

WheresWeed.com has a large and expanding reach with nearly 3 million pageviews per month. In addition, the WheresWeed mobile app, available in both iOS and Android, has been downloaded over 80,000 times, proving to be complementary to DVLP’s objective to capitalize on the massive growth curve in the marijuana space.

“The huge flood of new growers and producers is likely to create oversupply in the near term, narrowing margins for major producers,” says DVLP CEO Stavros Triant. “However, this should actually increase the net number of new consumers in the marketplace, further reinforcing the enormous growth potential for hub service providers in the space that are situated on high-traffic internet real estate, which is exactly how we view the Where’s Weed property.”

The company’s move into the lucrative C-store snack market was solidified with a material purchase order for CBD oils from a major distributor specializing in the snack foods and accessories to the convenience store and gas station market. The order represents significant progress as DVLP gears up its ready-made snack distribution strategy for its CBD products.

“We are extremely excited about the launch of our CBD product line with this distributor,” Triant states. “The C-Store strategy dovetails perfectly with our direct marketing strategy through our primary online retail channel, and we have indications from the distributor that, if this initial test order goes well, successive Purchase Orders could be significant and underpin strong sales growth in Q1 2019.”

Golden Developing Solutions, Inc. (DVLP), closed the day's trading session at $0.027, off by 6.90%, on 657,568 volume with 58 trades. The average volume for the last 3 months is 470,925 and the stock's 52-week low/high is $0.0125/$0.14.

Recent News

chart

ChineseInvestors.com (CIIX)

The QualityStocks Daily Newsletter would like to spotlight ChineseInvestors.com (CIIX).

ChineseInvestors.com (CIIX) was highlighted today in a report discussing how one of the more apparent emerging trends in the medical community is the increasing experimentation with CBD-based products and treatments as consumers are more open to alternative solutions to common diseases and ailments.

Founded in 1999, ChineseInvestors.com (CIIX) has become a leading financial information website for Chinese-speaking investors in the United States and China. Recognizing unprecedented opportunities in the U.S. cannabis industry, CIIX is also laying the groundwork to capitalize on growing demand for cannabidiol (CBD)-based nutrition and health products.

Through its primary website, www.ChineseInvestors.com, CIIX offers a variety of investor education products and services, including real-time market commentary, analysis and educational related services in Chinese language character sets; consultative services to smaller private companies considering becoming a public company; and advertising and public relations related support services.

At the center of this initiative is the ChineseInvestors Method, a unique integration of a disciplined investing process, web-based tools, personalized instructions and support. Using this strategy, CIIX provides reliable market information to help investors make informed investment decisions and meet their individualized financial goals.

CIIX is also leveraging its financial expertise to enter into the burgeoning CBD industry, which within a few years has grown from a relatively invisible sector to a billowing market expected to reach $2.1 billion in consumer sales by 2020.

The increasing demand for CBD-based products is a catalyst for innovative business endeavors. To this accord, CIIX has established a three-year development plan to capitalize on the convergence of CBD and the nutrition and health products market in mainland China, where the benefits of CBD oil have not been widely recognized.

Under a wholesale agreement with a reputable CBD health brand, CIIX is launching the world’s first online CBD health products store published in the Chinese language. The site, www.ChineseCBDoil.com, caters to a growing number of Chinese people awakening to the numerous health benefits of CBD oil for treatment of a variety of conditions such as anxiety, stress, poor sleep, Alzheimer’s disease, and more. CIIX expects to launch this website at the end of January 2017, and plans to sell CBD-infused products via online and in-store.

In conjunction, CIIX’s cannabis-focused “Yelp”-style mobile app is in development as a platform for Chinese people to review and discuss various cannabis products. The app will be the first marijuana social media mobile app designed for Chinese-speaking customers worldwide.

ChineseInvestors.com (CIIX), closed the day's trading session at $0.0011, off by 8.33%, on 18,485,335 volume with 60 trades. The average volume for the last 3 months is 5,012,335 and the stock's 52-week low/high is $0.0005/$0.0085.

Recent News

chart

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

ActionStockPicksAgressive StocksBetting On Wall StreetCannabisNewsWireGot Stocks?Got Stock Tips?Green Car StocksGreen Energy StocksGreen On The StreetHomeRunStocksMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireQualityStocks MediaQStocksQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsStock BeatsStocks To Buy NowTerrificStocksTiny GemsTip.usTouchdownStocksDaily ToutTraderPower

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.